Crinetics Financial Statements From 2010 to 2024

Stocks . USA . 
Stock . Crinetics Pharmaceuticals
CRNX Stock  USD 57.03  0.96  1.71%   
Crinetics Pharmaceuticals financial statements provide useful quarterly and yearly information to potential Crinetics Pharmaceuticals investors about the company's current and past financial position, as well as its overall management performance and changes in financial position over time. Historical trend examination of various income statement and balance sheet accounts found on Crinetics Pharmaceuticals financial statements helps investors assess Crinetics Pharmaceuticals' valuation, profitability, and current liquidity needs. Key fundamental drivers impacting Crinetics Pharmaceuticals' valuation are summarized below:
Gross Profit
-125.5 M
Market Capitalization
5.2 B
Enterprise Value Revenue
4.2 K
Revenue
1 M
Earnings Share
(3.70)
We have found one hundred twenty available fundamental signals for Crinetics Pharmaceuticals, which can be analyzed and compared to other ratios and to its rivals. All investors should make sure to validate all of Crinetics Pharmaceuticals prevailing market performance against the performance between 2010 and 2024 to make sure the company can sustain itself down the road.

Crinetics Pharmaceuticals Total Revenue

2.22 Million

Check Crinetics Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Crinetics Pharmaceuticals' main balance sheet or income statement drivers, such as Net Interest Income of 14.1 M, Interest Income of 14.1 M or Depreciation And Amortization of 760.2 K, as well as many indicators such as Price To Sales Ratio of 918, Dividend Yield of 0.0 or PTB Ratio of 4.02. Crinetics financial statements analysis is a perfect complement when working with Crinetics Pharmaceuticals Valuation or Volatility modules.
  
Check out the analysis of Crinetics Pharmaceuticals Correlation against competitors.
For more information on how to buy Crinetics Stock please use our How to Invest in Crinetics Pharmaceuticals guide.

Crinetics Pharmaceuticals Balance Sheet

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Total Assets667.1 M635.4 M173 M
Slightly volatile
Short and Long Term Debt Total54.3 M51.7 M8.7 M
Slightly volatile
Other Current Liabilities32.7 M31.2 M7.6 M
Slightly volatile
Total Current Liabilities46.1 M43.9 M11.2 M
Slightly volatile
Other Liabilities7.4 M7 M1.6 M
Slightly volatile
Property Plant And Equipment Net60.3 M57.4 M9.7 M
Slightly volatile
Accounts Payable3.9 M6.5 M2.3 M
Slightly volatile
Cash67.8 M54.9 M42.2 M
Slightly volatile
Non Current Assets Total64.3 M61.2 M10.6 M
Slightly volatile
Non Currrent Assets Other1.4 M1.3 M266.3 K
Slightly volatile
Other Assets0.951.0435.4 K
Slightly volatile
Long Term Debt130.4 K146.7 K159.7 K
Slightly volatile
Cash And Short Term Investments586.5 M558.6 M157.7 M
Slightly volatile
Net Receivables9.8 M9.4 M2 M
Slightly volatile
Common Stock Total Equity406.3 M387 M134.2 M
Slightly volatile
Common Stock Shares Outstanding33.4 M58.1 M24 M
Slightly volatile
Long Term Debt Total130.4 K146.7 K159.7 K
Slightly volatile
Non Current Liabilities Total54.9 M52.3 M19 M
Pretty Stable
Capital Surpluse245.8 M234 M100.3 M
Slightly volatile
Other Current Assets5 M6.2 M2.8 M
Slightly volatile
Total Liabilities101.1 M96.2 M30.2 M
Slightly volatile
Property Plant And Equipment Gross65.6 M62.5 M10.7 M
Slightly volatile
Short and Long Term Debt39.2 K44.1 K48 K
Slightly volatile
Preferred Stock Total Equity26.1 M34.2 M24.2 M
Slightly volatile
Total Current Assets602.9 M574.2 M162.4 M
Slightly volatile
Non Current Liabilities Other2.2 K2.3 K607.4 K
Pretty Stable
Short Term Debt4.4 M4.2 M926.3 K
Slightly volatile
Common Stock1.3 B1.2 B290.5 M
Slightly volatile
Property Plant Equipment4.2 M5.7 M2.5 M
Slightly volatile
Net Working Capital556.7 M530.2 M152.5 M
Slightly volatile
Short Term Investments528.8 M503.7 M179.5 M
Slightly volatile
Deferred Long Term Liabilities19.7 K20.7 K2 M
Slightly volatile
Capital Stock1.3 B1.2 B290.5 M
Slightly volatile
Capital Lease Obligations54.3 M51.7 M10.9 M
Slightly volatile

Crinetics Pharmaceuticals Income Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Net Interest Income14.1 M13.4 M2.6 M
Slightly volatile
Interest Income14.1 M13.4 M2.6 M
Slightly volatile
Depreciation And Amortization760.2 K1.1 M456.1 K
Slightly volatile
Selling General Administrative61 M58.1 M15.8 M
Slightly volatile
Total Revenue2.2 M4 M1.5 M
Slightly volatile
Other Operating Expenses238 M226.6 M63.7 M
Slightly volatile
Research Development177 M168.5 M48.5 M
Slightly volatile
Cost Of Revenue1 M1.1 M11.5 M
Pretty Stable
Total Operating Expenses238 M226.6 M63.7 M
Slightly volatile
Reconciled Depreciation854.4 K1.1 M479.2 K
Slightly volatile
Non Operating Income Net Other1.6 M1 M1.6 M
Pretty Stable

Crinetics Pharmaceuticals Cash Flow Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Stock Based Compensation43 M40.9 M10 M
Slightly volatile
Begin Period Cash Flow63.1 M34 M42 M
Slightly volatile
Depreciation760.2 K1.1 M456.1 K
Slightly volatile
Capital Expenditures4.9 M4.7 M1 M
Slightly volatile
End Period Cash Flow68.4 M56.2 M42.6 M
Slightly volatile
Change To Netincome35.2 M33.5 M9 M
Slightly volatile
Change To Liabilities23.3 M22.2 M5.6 M
Slightly volatile
Issuance Of Capital Stock188.1 M369 M171.5 M
Pretty Stable
Change To Account Receivables9.5 M14.6 M4.8 M
Slightly volatile

Financial Ratios

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio918515904
Pretty Stable
Days Sales Outstanding7277652.1 K
Slightly volatile
Stock Based Compensation To Revenue18.5910.201113.8191
Slightly volatile
Capex To Depreciation4.484.26962.0492
Pretty Stable
EV To Sales766514785
Pretty Stable
Payables Turnover0.220.2314.5248
Slightly volatile
Sales General And Administrative To Revenue13.7514.476523.137
Pretty Stable
Research And Ddevelopement To Revenue39.941.995373.3555
Pretty Stable
Capex To Revenue1.231.16820.6018
Slightly volatile
Cash Per Share5.069.61854.0635
Slightly volatile
Days Payables Outstanding1.7 K1.6 K483
Slightly volatile
Income Quality0.920.77520.8729
Slightly volatile
Net Debt To EBITDA0.01360.01431.4147
Slightly volatile
Current Ratio17.9613.066215.4621
Slightly volatile
Receivables Turnover0.470.494.1391
Slightly volatile
Graham Number29.1727.778710.9936
Slightly volatile
Capex Per Share0.08480.08070.0293
Slightly volatile
Revenue Per Share0.08660.06910.0647
Pretty Stable
Interest Debt Per Share0.07850.07470.0454
Slightly volatile
Debt To Assets0.01340.01510.0165
Slightly volatile
Days Of Payables Outstanding1.7 K1.6 K483
Slightly volatile
Ebt Per Ebit1.080.96370.9906
Very volatile
Quick Ratio17.913.066215.3852
Slightly volatile
Net Income Per E B T1.081.120.9986
Slightly volatile
Cash Ratio1.191.24939.7966
Slightly volatile
Days Of Sales Outstanding7277652.1 K
Slightly volatile
Free Cash Flow Operating Cash Flow Ratio1.121.02821.0341
Pretty Stable
Fixed Asset Turnover0.06640.06991.707
Slightly volatile
Debt Ratio0.01340.01510.0165
Slightly volatile
Price Sales Ratio918515904
Pretty Stable
Asset Turnover0.0060.00630.0341
Slightly volatile

Crinetics Pharmaceuticals Valuation Data

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Market Cap272.1 M306.1 M333.4 M
Slightly volatile
Enterprise Value359.8 M374.9 M332.5 M
Slightly volatile

Crinetics Fundamental Market Drivers

Cash And Short Term Investments558.6 M

Crinetics Upcoming Events

27th of February 2024
Upcoming Quarterly Report
View
2nd of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
27th of February 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

About Crinetics Pharmaceuticals Financial Statements

Crinetics Pharmaceuticals investors use historical fundamental indicators, such as Crinetics Pharmaceuticals' revenue or net income, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Crinetics Pharmaceuticals. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Current Deferred Revenue2.1 M2.2 M
Total Revenue4 M2.2 M
Cost Of Revenue1.1 M1 M
Stock Based Compensation To Revenue 10.20  18.59 
Sales General And Administrative To Revenue 14.48  13.75 
Research And Ddevelopement To Revenue 42.00  39.90 
Capex To Revenue 1.17  1.23 
Revenue Per Share 0.07  0.09 
Ebit Per Revenue(55.47)(58.25)

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
FFord Motor
GOOGAlphabet Inc Class C
CRMSalesforce

Additional Tools for Crinetics Stock Analysis

When running Crinetics Pharmaceuticals' price analysis, check to measure Crinetics Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Crinetics Pharmaceuticals is operating at the current time. Most of Crinetics Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Crinetics Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Crinetics Pharmaceuticals' price. Additionally, you may evaluate how the addition of Crinetics Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2024 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY